In the fourth segment of this roundtable series on the muscle invasive bladder cancer landscape, the panel discusses the use of immunotherapy in the adjuvant setting for bladder cancer, focusing on the use of nivolumab based on the results from the CheckMate-274 trial. The panel also discusses the potential synergy of combining enfortumab vedotin with pembrolizumab for patients who relapse after adjuvant immunotherapy, as well as considerations for re-challenging with immunotherapy after adjuvant use.
Adjuvant Therapy Challenges: When to Rechallenge Immunotherapy and Chemotherapy in Bladder Cancer
By Shilpa Gupta, MD, Kala Sridhar, MD, Karine Tawagi, MD, Benjamin Garmezy, MD - Last Updated: December 30, 2024Post Tags:Roundtable MIBC
Related Posts
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.